BGI
DRUG

B Group Inc’s Bright Minds Biosciences DRUG Stock Holding History

B Group Inc’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.74M Hold
67,500
– – 2.22% 16
2026
Q1 		$4.93M Buy
+67,500
New +$5.43M 3.65% 11

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

B Group Inc's DRUG Position: Q2 2026 in Review

B Group Inc held its Bright Minds Biosciences (DRUG) position steady in Q2 2026 at 67,500 shares worth $4.74M. The position accounts for 2.22% of the portfolio, ranked #16.

B Group Inc first reported a position in DRUG in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.93M in Q1 2026. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • B Group Inc held 67,500 shares of Bright Minds Biosciences worth $4.74M as of Q2 2026.
  • B Group Inc left its Bright Minds Biosciences share count unchanged in Q2 2026.
  • Bright Minds Biosciences made up 2.22% of B Group Inc's portfolio in Q2 2026, its #16 holding.
  • B Group Inc first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 2 quarters since.
  • B Group Inc's Bright Minds Biosciences position peaked at $4.93M in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on B Group Inc's 13F filing for Q2 2026, filed 14 Aug 2026.